GlassScriptPhysician profile
Janice D Dunkle
NPI 1275524704
$309.63
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.21 · 2020: $15.88 · 2021: $49.49 · 2022: $98.43 · 2023: $77.70 · 2024: $22.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $89.25 | 2019-2022 | |
| Oyster Point Pharma, INC. | $76.51 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $23.74 | 2023 | Durysta |
| Bausch & Lomb Americas INC. | $22.92 | 2024 | Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $16.38 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.82 | 2021 | |
| Horizon Therapeutics Plc | $13.13 | 2023 | Tepezza |
| Shire North American Group INC | $12.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Dunkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.